Citadel Advisors’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Citadel Advisors’s Portfolio TCON Stock Details TCON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-145	Closed	-$5.48K	–	15466
2023 Q1	$5.48K	Buy	145 +90	+164%	+$2.95K	﹤0.01%	13868
2022 Q4	$1.64K	Buy	+55	New	+$1.66K	﹤0.01%	14440
2022 Q1	–	Sell	-1,205	Closed	-$67K	–	14835
2021 Q4	$67K	Sell	1,205 -80	-6%	-$5.11K	﹤0.01%	13076
2021 Q3	$99K	Buy	1,285 +415	+48%	+$35.1K	﹤0.01%	12889
2021 Q2	$113K	Sell	870 -325	-27%	-$44.9K	﹤0.01%	12809
2021 Q1	$197K	Buy	+1,195	New	+$230K	﹤0.01%	11722

Other funds holding TCON

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's TCON Position: Q2 2023 in Review

Citadel Advisors sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q2 2023, closing a stake of 999 shares — an estimated $37.8K sold.

Citadel Advisors first reported a position in TCON in Q4 2017 and held it in 16 quarters. The position peaked at $144K in Q4 2020. 27 funds tracked by Wall St. Rank hold TCON as of Q2 2023.

Citadel Advisors reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Citadel Advisors sold 999 TRACON Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $37.8K.
Citadel Advisors first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 16 quarters.
Citadel Advisors's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $144K in Q4 2020.
27 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.